# EDGAR Filing Document

**Accession Number:** 0001771910
**File Stem:** 0000950103-23-003660
**Filing Date:** 2023-3
**Character Count:** 5653
**Document Hash:** 2129874c728e5e1ff0fe45b8b2087e0f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-23-003660.hdr.sgml**: 20230303

**ACCESSION NUMBER**: 0000950103-23-003660

**CONFORMED SUBMISSION TYPE**: SC TO-C

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20230303

**DATE AS OF CHANGE**: 20230303

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ADC Therapeutics SA
- **CENTRAL INDEX KEY:** 0001771910
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-C
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91517
- **FILM NUMBER:** 23702479

**BUSINESS ADDRESS:**
- **STREET 1:** BIOPOLE
- **STREET 2:** ROUTE DE LA CORNICHE 3B
- **CITY:** EPALINGES
- **STATE:** V8
- **ZIP:** 1066
- **BUSINESS PHONE:** 41 21 653 02 00

**MAIL ADDRESS:**
- **STREET 1:** BIOPOLE
- **STREET 2:** ROUTE DE LA CORNICHE 3B
- **CITY:** EPALINGES
- **STATE:** V8
- **ZIP:** 1066
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ADC Therapeutics SA
- **CENTRAL INDEX KEY:** 0001771910
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-C

**BUSINESS ADDRESS:**
- **STREET 1:** BIOPOLE
- **STREET 2:** ROUTE DE LA CORNICHE 3B
- **CITY:** EPALINGES
- **STATE:** V8
- **ZIP:** 1066
- **BUSINESS PHONE:** 41 21 653 02 00

**MAIL ADDRESS:**
- **STREET 1:** BIOPOLE
- **STREET 2:** ROUTE DE LA CORNICHE 3B
- **CITY:** EPALINGES
- **STATE:** V8
- **ZIP:** 1066

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**SCHEDULE TO**

**<br>TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF<br> THE SECURITIES EXCHANGE ACT OF 1934**

**ADC Therapeutics SA<br> (Name of Subject Company (Issuer))**

**ADC Therapeutics SA, as Issuer and Offeror<br> (Name of Filing Persons (Identifying status as offeror, issuer, or other person))**

**Options to purchase common shares, par value CHF 0.08 per share<br> (Title of Class of Securities)**

**H0036K147 for the common shares<br> (CUSIP Number of Class of Securities)**

**Peter J. Graham<br> ADC Therapeutics America, Inc.<br> 430 Mountain Avenue, 4th Floor<br> Murray Hill, NJ 07974<br> (908) 546-5556<br> (Name, address and telephone number of person authorized to receive notices and communications on behalf of filing persons)**

***Copy to:*<br> Deanna L. Kirkpatrick<br> Yasin Keshvargar<br> Kyoko Takahashi Lin<br> Davis Polk & Wardwell LLP<br> 450 Lexington Avenue<br> New York, NY 10017<br> (212) 450-4000**

☒ Check the box if filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

☐ third-party tender offer subject to Rule 14d-1.

☒ issuer tender offer subject to Rule 13e-4.

☐ going-private transaction subject to Rule 13e-3

☐ amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

☐ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

On March 3, 2023, ADC Therapeutics SA, a Swiss stock corporation (*société anonyme*) organized under the laws of Switzerland (the "<u>Company</u>"), transmitted the attached communication (the "<u>Communication</u>") to Company employees regarding the Company's upcoming option exchange program (the "<u>Exchange Program</u>").

*The Communication is for informational purposes only and is neither an offer to exchange nor a solicitation of an offer to exchange any of the Company's securities. The Exchange Program has not yet commenced. On the commencement date of the Exchange Program, a Tender Offer Statement on Schedule TO, including an Offer to Exchange Eligible Options for New Options (the "<u>Offer to Exchange</u>"), will be filed with the U.S. Securities and Exchange Commission (the "<u>SEC</u>") by the Company. Eligible option holders should carefully read those materials when they are available because they will contain important information, including the various terms and conditions of the Exchange Program. Eligible option holders may obtain free copies, when available, of the Tender Offer Statement on Schedule TO, including exhibits, from the SEC's website at www.sec.gov or by contacting the Company as set forth in the Offer to Exchange.*

ITEM 12. Exhibits.

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| (a)(1)(A) | Communication, dated March 3, 2023 |

---

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | | |
|:---|:---|:---|
| ADC THERAPEUTICS SA | ADC THERAPEUTICS SA | ADC THERAPEUTICS SA |
| By: | /s/ Ameet Mallik | /s/ Ameet Mallik |
|  | Name: | Ameet Mallik |
|  | Title: | Chief Executive Officer |

---

Date: March 3, 2023

## Ex-99.A1A

**Exhibit (a)(1)(A)**

![](image_002.jpg)

Town Hall March 3, 2023

![](image_003.jpg)

2 Recognizing Our People ▪ Stock option exchange offer ▪ Rolls out Monday, March 6th, ends on Monday, April 3 rd ▪ Webcast on Monday at 10 a.m. Eastern, recorded and posted on our intranet, Our ADCT ▪ Emails and instructions will be sent to you from Equity Methods AwardTraq CONFIDENTIAL – For ADCT Internal Use Only